{"id":"adalimumab-d2e7","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking TNF-alpha, adalimumab reduces inflammation and slows disease progression in various conditions. TNF-alpha is a cytokine that promotes inflammation and is involved in the pathogenesis of several autoimmune and inflammatory diseases. Adalimumab's mechanism of action is similar to other TNF inhibitors, such as infliximab and etanercept.","oneSentence":"Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:14.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT01166282","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Enthesitis Related Arthritis (ERA)","enrollment":46},{"nctId":"NCT01148225","phase":"PHASE3","title":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2010-11-23","conditions":"Uveitis","enrollment":424},{"nctId":"NCT01124838","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":261},{"nctId":"NCT01138657","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Uveitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-08","conditions":"Uveitis","enrollment":239},{"nctId":"NCT00573794","phase":"PHASE3","title":"Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2007-11-28","conditions":"Ulcerative Colitis","enrollment":592},{"nctId":"NCT01064856","phase":"PHASE3","title":"Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-02","conditions":"Peripheral Spondyloarthritis","enrollment":165},{"nctId":"NCT02750800","phase":"","title":"Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04-07","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":427},{"nctId":"NCT02668640","phase":"","title":"Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-05-01","conditions":"Rheumatoid Arthritis","enrollment":55},{"nctId":"NCT02897115","phase":"PHASE4","title":"A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment","status":"TERMINATED","sponsor":"AbbVie","startDate":"2016-09-12","conditions":"Axial Spondyloarthritis","enrollment":22},{"nctId":"NCT01736189","phase":"","title":"Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-10-11","conditions":"Rheumatoid Arthritis","enrollment":346},{"nctId":"NCT02198651","phase":"PHASE4","title":"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-01-05","conditions":"Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases","enrollment":149},{"nctId":"NCT01768858","phase":"","title":"Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-05","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":96},{"nctId":"NCT02333383","phase":"","title":"Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-31","conditions":"Ankylosing Spondylitis","enrollment":201},{"nctId":"NCT02533375","phase":"PHASE3","title":"Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-28","conditions":"Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese","enrollment":10},{"nctId":"NCT02185014","phase":"PHASE3","title":"Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-08-12","conditions":"Crohn's Disease","enrollment":252},{"nctId":"NCT01163292","phase":"","title":"Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT01550965","phase":"PHASE3","title":"A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Ulcerative Colitis","enrollment":463},{"nctId":"NCT00686374","phase":"PHASE3","title":"Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2008-05-01","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT01163617","phase":"PHASE2","title":"The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01808118","phase":"PHASE3","title":"Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-04-16","conditions":"Axial Spondyloarthritis","enrollment":673},{"nctId":"NCT02148718","phase":"PHASE4","title":"Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-06","conditions":"Moderate to Severe Crohn's Disease","enrollment":100},{"nctId":"NCT01235689","phase":"PHASE3","title":"Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-02-11","conditions":"Crohn's Disease","enrollment":252},{"nctId":"NCT00650156","phase":"PHASE1","title":"Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2007-06","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02349451","phase":"PHASE2","title":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-28","conditions":"Psoriatic Arthritis","enrollment":240},{"nctId":"NCT02016482","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Nail Psoriasis, Plaque Psoriasis","enrollment":217},{"nctId":"NCT01162421","phase":"PHASE4","title":"A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01958827","phase":"PHASE3","title":"A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-09","conditions":"Crohn's Disease","enrollment":28},{"nctId":"NCT01346501","phase":"","title":"Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-04","conditions":"Rheumatoid Arthritis","enrollment":172},{"nctId":"NCT00775437","phase":"PHASE3","title":"Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Juvenile Idiopathic Arthritis","enrollment":32},{"nctId":"NCT01646073","phase":"PHASE3","title":"Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-08","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT01644396","phase":"PHASE4","title":"An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-05","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":50},{"nctId":"NCT00939003","phase":"PHASE3","title":"Study of Adalimumab in Patients With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-07","conditions":"Axial Spondyloarthritis","enrollment":192},{"nctId":"NCT00853099","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-02","conditions":"Ulcerative Colitis","enrollment":274},{"nctId":"NCT01243671","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Intestinal Behçet's Disease","enrollment":20},{"nctId":"NCT01185288","phase":"PHASE4","title":"A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":309},{"nctId":"NCT01502423","phase":"PHASE2","title":"A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":61},{"nctId":"NCT01561313","phase":"PHASE2","title":"Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-03","conditions":"Rheumatoid Arthritis","enrollment":64},{"nctId":"NCT00808509","phase":"PHASE4","title":"A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-01","conditions":"Arthritis, Rheumatoid","enrollment":33},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT01265823","phase":"PHASE4","title":"Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-10","conditions":"Psoriasis","enrollment":150},{"nctId":"NCT00690573","phase":"PHASE3","title":"Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-05","conditions":"Juvenile Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT00195650","phase":"PHASE3","title":"Long Term Open Label Continuation Study","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-07","conditions":"Rheumatoid Arthritis","enrollment":846},{"nctId":"NCT00870467","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":334},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00445432","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-03","conditions":"Crohn's Disease","enrollment":82},{"nctId":"NCT00667355","phase":"PHASE3","title":"A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-02","conditions":"Ankylosing Spondylitis","enrollment":41},{"nctId":"NCT01114880","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2010-01","conditions":"Ankylosing Spondylitis","enrollment":344},{"nctId":"NCT00233571","phase":"PHASE3","title":"A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-06","conditions":"Rheumatoid Arthritis","enrollment":796},{"nctId":"NCT00195702","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-02","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00048542","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Arthritis, Juvenile Idiopathic","enrollment":171},{"nctId":"NCT00409682","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-04","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT00195715","phase":"PHASE3","title":"Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-09","conditions":"Crohn's Disease","enrollment":777},{"nctId":"NCT00195819","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-12","conditions":"Ankylosing Spondylitis","enrollment":82},{"nctId":"NCT00445939","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-02","conditions":"Crohn's Disease","enrollment":90},{"nctId":"NCT00603993","phase":"PHASE3","title":"Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-03","conditions":"Rheumatoid Arthritis","enrollment":88},{"nctId":"NCT00918255","phase":"PHASE2","title":"Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-04","conditions":"Hidradenitis Suppurativa","enrollment":154},{"nctId":"NCT00408629","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-11","conditions":"Ulcerative Colitis","enrollment":518},{"nctId":"NCT01231321","phase":"PHASE3","title":"A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT00085644","phase":"PHASE3","title":"Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-01","conditions":"Ankylosing Spondylitis","enrollment":315},{"nctId":"NCT00574249","phase":"PHASE3","title":"Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-11","conditions":"Chronic Plaque Psoriasis","enrollment":730},{"nctId":"NCT00195676","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-05","conditions":"Psoriasis","enrollment":1469},{"nctId":"NCT00566722","phase":"PHASE3","title":"Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-01","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT00348283","phase":"PHASE3","title":"Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-08","conditions":"Crohn's Disease","enrollment":135},{"nctId":"NCT00235872","phase":"PHASE3","title":"Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-08","conditions":"Rheumatoid Arthritis","enrollment":309},{"nctId":"NCT00235833","phase":"PHASE2","title":"Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-06","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT00385736","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-11","conditions":"Ulcerative Colitis","enrollment":576},{"nctId":"NCT00647270","phase":"PHASE3","title":"Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-12","conditions":"Rheumatoid Arthritis","enrollment":420},{"nctId":"NCT00513370","phase":"PHASE3","title":"A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-09","conditions":"Psoriasis","enrollment":203},{"nctId":"NCT00647400","phase":"PHASE2, PHASE3","title":"Adalimumab in Adult Japanese Subjects With Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-04","conditions":"Psoriasis","enrollment":147},{"nctId":"NCT00735787","phase":"PHASE4","title":"Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-08","conditions":"Psoriasis","enrollment":81},{"nctId":"NCT00427921","phase":"PHASE3","title":"Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-01","conditions":"Crohn's Disease","enrollment":304},{"nctId":"NCT00761514","phase":"PHASE4","title":"Evaluation of Quality of Life Changes in Puerto Rican Subjects With Active Rheumatoid Arthritis Treated With Humira","status":"TERMINATED","sponsor":"Abbott","startDate":"2006-11","conditions":"Rheumatoid Arthritis","enrollment":14},{"nctId":"NCT00448383","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Rheumatoid Arthritis","enrollment":6610},{"nctId":"NCT00235820","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-07","conditions":"Psoriasis","enrollment":271},{"nctId":"NCT00650026","phase":"","title":"Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis","status":"APPROVED_FOR_MARKETING","sponsor":"Abbott","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00649545","phase":"","title":"Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis","status":"APPROVED_FOR_MARKETING","sponsor":"Abbott","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00649922","phase":"PHASE4","title":"Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-10","conditions":"Rheumatoid Arthritis","enrollment":226},{"nctId":"NCT00650390","phase":"","title":"Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab","status":"APPROVED_FOR_MARKETING","sponsor":"Abbott","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT00647920","phase":"PHASE3","title":"Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-07","conditions":"Rheumatoid Arthritis","enrollment":47},{"nctId":"NCT00647491","phase":"PHASE2, PHASE3","title":"A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2004-02","conditions":"Rheumatoid Arthritis","enrollment":352},{"nctId":"NCT00645905","phase":"PHASE2","title":"Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-06","conditions":"Psoriasis","enrollment":148},{"nctId":"NCT00646178","phase":"PHASE3","title":"Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-06","conditions":"Arthritis, Psoriatic","enrollment":102},{"nctId":"NCT00645814","phase":"PHASE2","title":"Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-03","conditions":"Psoriasis","enrollment":148},{"nctId":"NCT00646386","phase":"PHASE2","title":"Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-03","conditions":"Arthritis, Psoriatic","enrollment":315},{"nctId":"NCT00646191","phase":"PHASE2","title":"Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-03","conditions":"Psoriasis","enrollment":137},{"nctId":"NCT00645892","phase":"PHASE2","title":"Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-11","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT00234845","phase":"PHASE3","title":"Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-03","conditions":"Rheumatoid Arthritis","enrollment":148},{"nctId":"NCT00195689","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-08","conditions":"Psoriatic Arthritis","enrollment":400},{"nctId":"NCT00049751","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Rheumatoid Arthritis","enrollment":3000},{"nctId":"NCT00055523","phase":"PHASE2","title":"A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-04","conditions":"Crohn's Disease","enrollment":300},{"nctId":"NCT00235105","phase":"PHASE2, PHASE3","title":"D2E7-Early AS","status":"UNKNOWN","sponsor":"Charite University, Berlin, Germany","startDate":"2005-03","conditions":"Ankylosing Spondylitis","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","adalimumab","Humira"],"phase":"phase_3","status":"active","brandName":"adalimumab (D2E7)","genericName":"adalimumab (D2E7)","companyName":"Abbott","companyId":"abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}